SOURCE: ViroCyt, Inc.

ViroCyt, Inc.

October 20, 2016 08:30 ET

ViroCyt® Develops Rapid Detection System for Enterovirus 71

BROOMFIELD, CO--(Marketwired - October 20, 2016) - ViroCyt®, the innovator in rapid virus quantification, and recently acquired by Sartorius, a leading international pharmaceutical and laboratory equipment provider, announced today the addition of another member of its ViroTag® portfolio of antibody-based detection reagents: ViroTag EV71.

Enterovirus 71 or EV71 causes epidemics of hand, foot and mouth disease (HFMD) as well as severe neurological diseases in children, primarily in Asia. Recent efforts have resulted in the approval of a vaccine manufactured by Sinovac Biotech Limited using inactivated EV71 virus, and several other vaccine candidates are currently being developed. As is the cause for any virus-based product, the ability to rapidly quantify the virus during the growth, harvest and purification process is crucial for the manufacture and release of consistent supplies of high-quality vaccines.

In response, ViroCyt has created an EV71-specific detection system that-when combined with the Virus Counter 3100 instrument-enables precise quantification of the virus during a one-minute analysis. "Based on significant customer input, ViroCyt identified substantial demand for ViroTag EV71, especially in the emerging markets of China, Japan, South Korea, Taiwan and Singapore," said Dr. Daniel Galbraith, Chief Scientist with Sartorius Stedim BioOutsource. "An increasing amount of the global vaccine effort is based in these countries, and the ability to provide a biologically-relevant means of accelerating the creation of life-saving vaccines for the severely debilitating diseases caused by the Enterovirus 71 virus is a real-world game-changer."

Added Dr. Michael Artinger, Vice President of Marketing and Strategic Partnering at ViroCyt, "Sartorius has for a number of years been developing a strategy with both reagents and equipment to support manufacturers of virus as a product. The acquisition of ViroCyt and its unique product portfolio provides them with an important tool to monitor the viral manufacturing process and as such will revolutionize the development of new virus products. Our new kit for Enterovirus 71 is another in a list of innovative products we will bring to market in close consultation with our key customers."

About ViroTag

ViroCyt has developed a novel approach enabling direct, biologically-specific quantification of viruses in minutes rather than the days or weeks required by more traditional methods. Marketed under the tradename ViroTag®, this product category utilizes a fluorescently-labeled, high-affinity antibody targeted to the virus of interest. During a 1-minute sample analysis, the preparation is evaluated with the Virus Counter® 3100, an instrument developed expressly for the purpose of real-time virus quantification. The growing list of products includes kits to detect Adenovirus, Adeno-Associated Virus, Baculovirus and Influenza.

About ViroCyt, Inc.

ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. The company was acquired in July, 2016 by Sartorius, a leading international pharmaceutical and laboratory tools provider. Additional information can be found at http://www.virocyt.com.

About Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.1 billion euros in 2015. More than 6,200 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.

Image Available: http://www.marketwire.com/library/MwGo/2016/10/19/11G118607/Images/virocyt-b93b709a1b19b16ba91f75d181d02c68.jpg

Contact Information

  • Contact Information

    Dr. Michael Artinger
    Vice President, Marketing & Strategic Partnering

    ViroCyt, Incorporated
    +1-720-599-3700
    martinger@virocyt.com